Article info
Clinical and epidemiological research
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
- Dr J Askling, Clinical Epidemiology Unit, M9:01, Karolinska Institutet at Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden; johan.askling{at}ki.se
Citation
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
Publication history
- Accepted April 23, 2008
- First published May 8, 2008.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group and European League Against Rheumatism